NEW YORK (GenomeWeb) – ImmusanT today announced it has raised $12 million in Series B financing from Vatera Healthcare Partners to continue developing Nexvax2, an immunotherapy for celiac disease, as well as a companion diagnostic to pair with the treatment and a standalone blood-based diagnostic.

The Cambridge, Mass.-based firm will continue to develop its whole-blood functional T-cell test as both a companion diagnostic to identify patients most likely to respond to Nexvax2 and as a standalone test.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.